CBL-514 Injection
Sponsors
Caliway Biopharmaceuticals Co., Ltd.
Conditions
CelluliteDercum's DiseaseSubcutaneous Fat
Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
CompletedNCT04897412
Start: 2022-02-14End: 2023-03-22Updated: 2023-04-24
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
CompletedNCT05736107
Start: 2023-05-30End: 2024-05-20Updated: 2024-07-22
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
CompletedNCT05836779
Start: 2023-05-10End: 2024-01-05Updated: 2026-07-09
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
CompletedNCT06005441
Start: 2023-11-10End: 2024-10-18Updated: 2024-12-05
A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
Active, not recruitingNCT06303570
Start: 2024-11-27End: 2026-04-01Updated: 2026-04-14
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
RecruitingNCT07608770
Start: 2026-06-01End: 2027-11-01Target: 250Updated: 2026-06-04
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Not yet recruitingNCT07608757
Start: 2027-02-01End: 2028-06-01Target: 250Updated: 2026-05-29
Phase 3
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
Not yet recruitingNCT07140939
Start: 2026-07-01End: 2027-07-01Target: 300Updated: 2026-03-30
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
Not yet recruitingNCT07526974
Start: 2026-10-01End: 2027-10-01Target: 320Updated: 2026-04-14
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Not yet recruitingNCT07733947
Start: 2026-12-01End: 2028-09-01Target: 300Updated: 2026-07-30